SCHEMBL4075669

SCHEMBL4075669

O=C(NCc1ccccc1N1CCCCC1)N1CC(OC(c2ccccc2Cl)c2ccccc2Cl)C1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.44
FABP4 P15090 1/20 0.44
KCNQ2 O43526 2/20 0.43
SCN2A Q99250 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
FAAH O00519 5/20 0.41
ALDH1A1 P00352 3/20 0.41
LIPG Q9Y5X9 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
CNR1 P21554 2/20 0.38
CYP2C19 P33261 2/20 0.38
CNR2 P34972 2/20 0.38
KCNH2 Q12809 1/20 0.38
MGLL Q99685 1/20 0.38
CYP3A4 P08684 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5821899 0.84 FABP3 (0.43) FABP3FABP4KCNQ2SCN2ASCN10A
SCHEMBL4083665 0.78 CNR1 (0.57) FAAHCNR1CNR2
SCHEMBL4084884 0.77 MAPT (0.44) FAAHMAPT
SCHEMBL4087343 0.76 CYP2C19 (0.41) FAAHMEN1KMT2ACNR1CYP2C19
SCHEMBL4084883 0.75 HPGD (0.43) FAAHALDH1A1MEN1MAPTKMT2A
SCHEMBL4077693 0.75 MEN1 (0.54) FAAHALDH1A1MEN1KMT2ACNR1
SCHEMBL29574541 0.75 MEN1 (0.54) FAAHALDH1A1MEN1KMT2ACNR1
SCHEMBL4075655 0.74 CNR1 (0.51) FAAHCNR1
SCHEMBL4075586 0.74 NPC1 (0.44) FAAHALDH1A1MEN1MAPTKMT2A
SCHEMBL4075813 0.74 CNR1 (0.46) FAAHMEN1KMT2ACNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620395-B1 AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS VERNALIS RES LTD (GB) 2009-12-30 EP disclosed
US-7504522-B2 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders VERNALIS RESEARCH LIMITED (GB) 2009-03-17 US disclosed
US-20070054891-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders VERNALIS RESEARCH LIMAITED (GB) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054891-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders CNR1, CNR2, GPR119 FABP3 2163/4885FABP4 403/4885KCNQ2 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.